Table 2.
Outcome Variables at Baseline and Model-Adjusted Changes Over Time
| Outcome Variable | Baseline Mean (SD) in SWAD | Baseline Mean (SD) in STAY | Mean (95% CI) Change in SWADa | Mean (95% CI) Change in STAYa | Difference Between Means, SWAD-STAY (95% CI)a |
|---|---|---|---|---|---|
| Weight, kg | 80.2 (25.7) | 80.8 (23.0) | 2.4 (1.5–3.3) | 0.2 (−.4 to .8) | 2.1 (1.2–3.1)*** |
| BMI, kg/m2 | 30.6 (8.9) | 30.9 (8.2) | 0.9 (.5–1.2) | 0.1 (−.1 to .3) | 0.8 (.4–1.1)*** |
| Body fat (%)b | 33.9 (11.5) | 35.0 (11.6) | 1.7 (.9–2.5) | 0.3 (−.2 to .9) | 1.4 (.5–2.2)* |
| Body circumference measurements, cm | |||||
| Waist | 99.2 (17.1) | 99.6 (16.2) | 2.4 (1.5–3.4) | 0.4 (−.2 to 1.0) | 2.0 (1.0–3.0)*** |
| Hip | 104.5 (15.5) | 106.3 (14.9) | 1.4 (.6–2.3) | −0.4 (−1.0 to .1) | 1.9 (1.0–2.7)*** |
| Arm | 32.8 (6.6) | 33.0 (6.4) | 0.7 (.4–1.0) | 0.1 (−.1 to .3) | 0.6 (.2–.9)** |
| Thigh | 53.1 (10.6) | 54.1 (9.9) | 0.9 (.3–1.4) | −0.1, (−.5 to .2) | 1.0 (.4–1.6)* |
| Waist to hip ratio | 0.95 (0.09) | 0.94 (0.08) | 0.011 (.003–.019) | 0.009 (.004–.014) | 0.002 (−.006 to .010) |
*P < .01, **P < .001, ***P < .0001.Abbreviations: ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval; INSTI, integrase strand transfer inhibitor; SD, standard deviation; STAY, women who remained on non-INSTI ART during follow-up; SWAD, women who switched to or added an INSTI to ART.
aFrom models adjusted for age, site, race/ethnicity, income, smoking status, education, and baseline ART.
bUsing a bioelectrical impedance analysis: [(body fat/weight_kg)*100] = (%).